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SUMMARY 
Prospective observational studies support a role of long-chain n-3 PUFA in the primary 
prevention of atherosclerotic cardiovascular disease, however, RCTs have often reported 
neutral findings. There has been also a long history of debate about potential harmful effects 
of high n-6 PUFA intake, although this notion is not supported by prospective observational 
studies or RCTs. Health effects of dietary PUFA may be influenced by delta-5 and delta-6 
desaturases, key enzymes in the metabolism of PUFA. The activity of these enzymes and its 
modulation by variants in encoding genes (FADS1-2-3 gene cluster) are linked to several 
cardiometabolic traits. This review will furthermore consider non-genetic determinants of 
desaturase activity, which have the potential to modify tissue PUFA availability. Finally, it 
will discuss the consequences of altered desaturase activity in the context of PUFA intake, i.e. 
gene-diet interactions, and their clinical and public health implications. 
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INTRODUCTION 
Fatty acids present in different lipid molecules are the major components of dietary fats. The 
physical and chemical characteristics and the nutritional and health effects of dietary fatty 
acids are influenced greatly by the kinds and proportions of the component fatty acids.1 The 
predominant fatty acids are either saturated fatty acids (SFA) or contain carbon-carbon double 
bonds: monounsaturated fatty acids (MUFA) with one and polyunsaturated fatty acids 
(PUFA) with two or more double bounds. While foods rich in SFA (e.g. fatty meat and dairy 
products, coconut and palm oil, confectionary and cakes) and MUFA (some vegetable oils, 
meats) contribute to the intake of these fatty acids, they can also be produced endogenously. 
In contrast, the PUFA linoleic acid (LA) and α-linolenic acid (ALA) are essential fatty acids 
and mainly derived from vegetable oils, nuts and seeds.2 Humans have a limited capacity to 
synthesize eicosapentaenoic acid (EPA), and to a lesser extent docosahexaenoic acid (DHA), 
from ALA.3 While EPA and DHA as long chain (LC) n-3 PUFA are therefore not strictly 
essential, they are consumed together as fish or fish oil capsules (either over the counter 
(OTC) dietary supplements or pharmaceutical grade preparations). Microalgae is a dietary 
source for vegetarians. Although the intake of PUFA has been a cornerstone of dietary 
recommendations, controversy remains about the optimal absolute and relative intakes of the 
main dietary n-3 and n-6 PUFA.2,3 
 
Prospective observational studies support the role of LC n-3 PUFA, EPA and DHA in the 
primary prevention of atherosclerotic cardiovascular disease (ASCVD), with the underlying 
mechanisms of action widely described.4,5 However, recent RCTs have often reported neutral 
findings,6,7 which has called into question the use of fish oil supplementation as a strategy to 
reduce the risk of heart disease or stroke.8 There has been also a long history of debate about 
potential harmful effects of high n-6 PUFA intake, specifically if their intakes far exceed 
those of n-3 PUFA.9 In light of the fact that n-6 PUFA account for the majority of PUFA in 
normal diets,10 it is important to shed light on the complex epidemiology and metabolism 
related to PUFA intake and to better understand the clinical and public health implications of 
both n-3 and n-6 PUFA intake for cardiometabolic diseases such as type 2 diabetes (T2DM) 
and ASCVD. 
 
This review will start with a summary of evidence relating intake of n-3 and n-6 PUFA to 
cardiometabolic diseases. It will then address how PUFA metabolism is linked to delta-5 and 
delta-6 desaturases and the evidence linking enzymes activities and their modulation by 
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genetic determinants, specifically genetic variants in the FADS1-2-3 gene cluster, to several 
cardiometabolic traits. Finally, it will discuss the consequences of altered desaturase activity 
in the context of PUFA intake. i.e. gene-diet interactions, and their clinical and public health 
implications. 
 
N-3 PUFA intake and its relation to ASCVD and T2DM 
Prospective cohort studies consistently support the role of EPA and DHA in the primary 
prevention of ASCVD, with underlying mechanisms including an impact on plasma 
triglycerides and lipoprotein size, inflammation and plaque stability, vascular function, and 
arrhythmias.4,5,11 Existing RCTs on clinical endpoints are largely secondary prevention (e.g. 
GISSI 12 and Alpha Omega 13) or mixed primary and secondary prevention trials (e.g. 
JELIS,14 REDUCE-IT 15 and the Risk and Prevention Study 16) (Table 1). Only VITAL was a 
primary prevention study recruiting healthy men and women with no history of CVD.7 Earlier 
secondary prevention trials reported a 20-30% reduction in cardiovascular deaths.12,14,17 
Similarly, advice to consume fatty fish lowered total mortality.18 However, subsequent RCTs 
have often observed no effect on ASCVD incidence or deaths.6,7,13,15,16,19 These have been 
summarized by several systematic reviews 17,20 which have questioned a role of 
supplementation with LC n-3 PUFA in secondary ASCVD prevention. This notion seems 
generally supported by recent RCTs. For instance, no benefit of EPA+DHA supplementation 
to prevent ASCVD was observed among patients with T2DM or prediabetes in the ASCEND 
study 6 or healthy individuals in the VITAL study.7 However, REDUCE‐ IT observed 
significantly lower risk of ASCVD and borderline significant reduction in mortality with high 
doses of EPA (4g per day) among patients with established ASCVD or risk factors (including 
high triglycerides).15 Up to 4g EPA/DHA is approved as an alternative to fibrates as a 
triglyceride reducing agent.21 The effect-size in REDUCE-IT (hazard ratio 0.75) is suggestive 
of benefits beyond triglyceride lowering.4,5 Due to the chemical form used (i.e. icosapent 
ethyl, a highly purified and stable EPA ethyl ester) these results cannot be directly 
extrapolated to OTC formulations. These RCTs have been included in two very recent meta-
analysis. One analysis, including 13 RCTs, concluded that LC n‐ 3 PUFA supplementation 
lowers risk for MI, coronary heart disease (CHD) death, total CHD, ASCVD death, and total 
ASCVD, with risk reductions linearly related to dose.22 According to the latest Cochrane 
meta-analysis, LC n-3 PUFA supplementation reduces CHD death and CHD events by 
approximately 10%, although no significant effect is evident for total ASCVD events or for 
stroke.23 
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Direct comparison between observational and trial evidence has several obstacles. 
Observational studies are generally prone to confounding, thus other factors associated with 
LC n-3 PUFA intake might explain observed benefits. Also, observational studies usually 
capture dietary sources of LC n-3 PUFA (fish intake) where the LC n-3 PUFA are 
predominantly in the triglyceride form with some phospholipid EPA and DHA also present, 
rather than supplementation with isolated PUFA. Additionally, when comparing the outcomes 
from individual RCTs it is important to consider the chemical form and dose of n-3 PUFAs, 
whether the formulation contains both EPA and DHA and the ratio, and whether the 
supplement used was OTC or a prescription grade preparation. Supplemental (OTC) or 
prescription EPA and DHA is available as a free fatty acid, triglyceride, phospholipid or ethyl 
ester forms. The bioavailability of fatty acids from ethyl esters is known to be substantially 
lower than from the other forms, particularly when consumed fasting or in a low-fat meal.24 
Although this is unlikely to have been an issue in REDUCE-IT given the high dose of EPA 
administered,15 in ORIGIN,19 the Risk and Prevention Study,16 ASCEND,6 and VITAL 7 
reduced EPA+DHA bioavailability may have contributed to the lack of efficacy observed 
(Table 1). Furthermore, more aggressive use of cardiovascular medications over the last two 
decades may lower the therapeutic opportunity since EPA and DHA having overlapping 
targets with the prescribed drugs. For example, both fibrates and EPA/DHA mediate 
triglyceride lowering via PPAR-alpha dependent mechanisms.25 However, subgroup analyses 
in ORIGIN, VITAL or REDUCE-IT and the positive impact of EPA intervention in statin 
users in the JELIS trial do not support a general stronger benefit of LC n-3 PUFA 
supplementation among non-users of cardiovascular medication.7,14,15,19 Still, recent RCTs 
may have the limitation of a high habitual EPA and DHA intake in the trial participants at 
baseline.17 For example, in VITAL, subgroup analysis indicated an effect of EPA+DHA on 
major cardiovascular events (HR 0·81) and myocardial infarction (MI) incidence (HR 0·64) 
in those with lower fish intake at baseline (<1·5 servings per week) but not in those with 
higher intakes (≥1·5 servings per week).7 While such a difference was not observed in the 
ORIGIN trial,19 a systematic evaluation of effect modification by baseline n-3 PUFA status 
across existing trials is so far lacking, as is an RCT which specifically tests the effect of 
supplementation among individuals with low habitual n-3 PUFA intake.  
 
Also noteworthy, individual RCTs point towards beneficial effects on specific cardiovascular 
endpoints as secondary outcome measures. For instance, EPA+DHA intervention reduced the 
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risk of vascular deaths among patients with prevalent CHD according to a meta-analysis of 
RCTs 26 and in patients with diabetes in the ASCEND study.6 Supplementation with LC n-3 
PUFA reduced risk of MI in VITAL.7 Furthermore, there is no direct comparison of EPA vs 
DHA in primary or secondary prevention trials. Such evidence is needed to inform policy, if 
individual EPA and DHA recommendations are to be developed. Although DHA has emerged 
as being more effective than EPA in reducing plasma triglycerides and improving vascular 
function,27 high dose EPA reduced incident ASCVD in the REDUCE-IT trial.15 The 
STRENGTH trial,28 with a study population comparable to REDUCE-IT,15 has recently been 
stopped due to its low likelihood of demonstrating a benefit.29 Relative to REDUCE-IT (4g 
EPA as ethyl ester), STRENGTH supplemented with slightly lower dose of and different form 
of LC n-3 PUFA (2·2g EPA and 0·8g DHA as free fatty acids). These recent findings suggest 
that the formulation of the LC n-3 PUFA tested may be very important.  
 
Similar to LC n-3 PUFA, prospective cohorts indicate an approximate 10-15% reduced risk of 
cardiovascular events associated with higher ALA intake.30,31 These observational data are 
supported by RCTs: a recent Cochrane review concluded that ‘increased ALA may slightly 
reduce risk of cardiovascular events and probably reduces risk of CHD mortality and 
arrhythmia’ with modest effect sizes.32 However, large-scale long-term trials on ALA 
supplementation are rather scarce (Table 1). In the only trial meeting this criteria - the Alpha 
Omega trial - providing an ALA-rich margarine to persons with previous MI did not 
significantly reduce major ASCVD events compared to a placebo margarine, although the 
effect size points towards benefits.13 Any impact of ALA might be due to both an indirect 
effect on EPA status and a direct effect on other cardiometabolic pathways or risk factors. 
 
Furthermore, there is little indication that EPA and DHA improve indices of glycaemia and 
insulin sensitivity or reduce incident T2DM risk.33 In a pooled analyses of cohort studies, sea 
food and fish derived LC n-3 PUFA had no clear association with T2DM risk.34 That LC n-3 
PUFA might be less important with regard to diabetes compared to ASCVD risk is supported 
by Mendelian randomization studies where triglyceride lowering reduced ASCVD risk but not 
diabetes risk.35,36 In contrast, ALA was modestly inversely linked to diabetes risk.34 An 
inverse association between ALA plasma levels and T2DM risk was also seen in the EPIC-
InterAct study.37 However, evidence from RCTs on ALA supplementation with T2DM as 
endpoint is largely missing so far.33 
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N-6 PUFA intake and its relation to ASCVD and T2DM 
Several older trials on the effect of cholesterol-lowering PUFA-rich diets replacing SFA from 
dairy and meat on risk of ASCVD and death have been conducted (Table 1).38-44 In these 
trials, mostly LA as n-6 PUFA was used or a mixture of n-6 (LA) and n-3 (ALA) from 
vegetable oils. PUFA was associated with a moderate reduction of total CHD and fatal deaths 
relative to SFA in one meta-analyses.45 The risk reduction (10% for each 5% energy from 
SFA substituted with PUFA) accorded well with the lowering of serum cholesterol and 
cholesterol/HDL ratio in these trials. Similarly, a recent Cochrane review supports a risk 
reduction for MI if n-6 PUFA replace SFA,46 although no clear benefit was observed for 
overall ASCVD. No evidence was found for dose-response, but there was a suggestion of 
greater ASCVD protection in participants with lower baseline n-6 PUFA intake across 
outcomes. The trial findings are fairly consistent with a pooled analysis of 11 prospective 
cohort studies which specifically evaluated a substitution of PUFA (mostly LA) for SFA 47 
and a meta-analysis of 13 cohort studies on LA versus SFA.48 Notably, in prospective cohort 
studies with n-6 PUFA biomarkers (circulating or tissue LA levels), higher LA levels were 
associated with lower risk of all ASCVD outcomes, including ASCVD mortality, even after 
taking n-3 PUFA levels into account.49 According to a recent meta-analysis of cohort studies, 
higher LA intake and tissue levels are related not only to lower ASCVD mortality, but also 
total and cancer mortality.50 However, secondary analyses of older trials suggest that high 
intake of LA in combination with ALA is more favorable than high n-6 PUFA alone, which 
may have unwanted effects at higher doses.51-53 These older trials are, however, difficult to 
interpret because of the short duration of some trials, small numbers of events, high drop-out 
rates and confounding by trans-fats that were commonly abundant in PUFA-rich margarines 
used (Table 1). Still, meta-analyses of trials show somewhat inconsistent results for n-6 
PUFA, depending on study inclusions.45,46,53-56 Taken together, evidence from RCTs and 
prospective cohort studies suggests that plant oils rich in LA seem to be moderately protective 
against CHD, especially MI. 
 
Regarding n-6 PUFA intake and T2DM risk, there are no available data from trials designed 
to investigate diabetes incidence as an outcome.33 However, when taking into account short-
term feeding trials and prospective cohort studies using n-6 biomarkers or food 
questionnaires, a previous review suggests inverse associations between n-6 PUFA (LA in 
particular) and incident T2DM.57 This has been confirmed in several more recent cohort 
studies, including the pan-European EPIC-InterAct study,37 and the pooled meta-analyses 
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from the FORCE consortium.58 In the latter which measured LA and arachidonic acid (AA) in 
circulating lipids in prospective cohorts, LA, but not AA, was inversely and linearly 
associated with incident T2DM, and this robust association was not modified by n-3 PUFA 
status.58 In support, a quite large number of small and mostly shorter-term randomized 
feeding trials indicate that PUFA, when isocalorically compared with SFA or carbohydrates, 
improve markers of insulin sensitivity and glycemic control.59 Still, more definitive RCTs of 
longer duration are lacking.33 
 
Role of n-6/n-3 ratio  
Concern that consuming a relatively high proportion of dietary n-6 fats compared with n-3 
fats has detrimental effects, particularly on inflammatory status, have generally not been 
supported by study evidence. Indeed, several feeding trials showed that increasing n-6 PUFA 
(e.g. LA) while keeping n-3 intake unchanged, thus resulting in several-fold higher n-6/n-3 
ratio, has no adverse effects on either multiple markers of inflammation or oxidative stress,60 
not even under energy excess conditions at very high LA intake.61 In line with these findings, 
a recent meta-analysis did not find evidence to suggest an important role of the n-6/n-3 ratio 
on glucose metabolism.33 While longer term RCTs on n-6 PUFA are insufficient to conclude 
on the relevance of the n:6/n-3 ratio,46 prospective cohort studies do not indicate any adverse 
role of a high n-6/n-3 ratio.62 The reasons for the lack of apparent importance of the n-6/n-3 
ratio to predict cardiometabolic disease or inflammation probably include the fact that this 
ratio is partly based on a number of incorrect and simplified assumptions,63 e.g. n-6 PUFA 
overall is proinflammatory, n-6 PUFA and LA in particular have adverse effects on CVD risk 
(while in fact both n-6 and n-3 PUFA are related to lower risk), and lowering intake of LA 
will lower AA levels (in contrast, supplementing LA does not increase AA plasma or adipose 
tissue levels 61,64). In addition, a clear problem arises when combining different n-6 (and n-3) 
PUFA despite distinct inflammatory and cardiovascular effects of individual PUFA as well as 
their different metabolites.63 It would be important to standardize the calculation of this ratio, 
as different studies have used somewhat different ratios (e.g. considering all n-3 PUFA or 
EPA and DHA only). Also, this ratio calculated from dietary intake data cannot be compared 
with a ratio calculated from plasma or tissue PUFA levels. 
 
PUFA metabolism 
PUFA fulfill various functions within the human body, besides being a source of energy. 
They are central structural components of the phospholipid layer of cell membranes, 
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influencing membrane fluidity and selective permeability. Furthermore, PUFA can directly 
influence several metabolic pathways, being ligands for transcription factors like sterol 
regulatory element binding protein 1 (SREBP-1), nuclear factor κB (NF-κB), hepatocyte 
nuclear factor 4α (HNF-4α), and peroxisome proliferator-activated receptors (PPARs), which 
play a central role in lipid metabolism. PUFA are furthermore substrates for the formation of 
various lipid-related metabolites, e.g. eicosenoids, leukotrienes, prostaglandins, 
thromboxanes, lipoxins, endocannabinoids, or resolvins, which themselves are highly 
bioactive. In this context, the sphingolipids ceramides are an additional interesting group of 
lipid molecules. Prospective studies have linked ceramides to cardiometabolic risk 65,66 and 
experimental data suggest causal links to insulin resistance, and potentially also ASCVD.67 
Interestingly, n-6 PUFA (LA) decrease several plasma ceramide species as compared with 
SFA.61  
 
Importantly, although the essential precursor PUFA LA and ALA are the main PUFA sources 
in the diet, other PUFA can be produced endogenously, although the bioconversion efficiency 
to DHA is limited.3 The bioconversion of LA and ALA to the longer chain PUFA (γ-linolenic 
acid [GLA], dihomo-γ-linolenic acid [DGLA], AA, EPA, DHA) is catalyzed by elongases and 
desaturases – with the delta-6 and delta-5-desaturases being the key enzymes in this process 
(Figure 1). Specifically, delta-6-desaturase is considered the rate limiting step of conversion 
of LA and ALA to downstream metabolites. Noteworthy also, both n-6 and n-3 PUFA 
compete for the same enzymes in this processes, although a preferential affinity to n-3 PUFA 
exists.68 PUFA are the main dietary component that regulate the activity of these desaturases. 
In a rodent model, both desaturases seem to be suppressed by dietary PUFA.69 A stable 
isotope study showed that increased LC n-3 PUFA intakes inhibits ALA bioconversion.3 
 
PUFA often exert their physiological effects through a host of oxidative bioactive products 
(Figure 1), collectively named ‘oxylipins‘, produced by the action of cycloxygenases 
(encoded by COXs), lipoxygenases (encoded by ALOXs), and some members of CYP450 
superfamily (CYP1-4 families). Oxylipins have long been known to have a pro-inflammatory 
effect as thromboxanes (TXs), prostaglandins (PGs) and leukotrienes (LTs). TXs, 2 series-
PGs and the 4 series-LTs are AA-derived while EPA metabolism produces 3 series-PGs and 5 
series-LTs. EPA products are generally less pro-inflammatory than their AA counterparts.70 
However, the inflammatory impact of AA or EPA derivates is nuanced both producing pro- or 
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anti-inflammatory products. For example, AA-derived PGI2 is traditionally known to inhibit 
platelet aggregation.71 
 
In addition to competing with AA, recent studies show that EPA and DHA play a direct anti-
inflammatory and resolving role through the production of signalling molecules, named 
Specialised Pro-resolving Mediators (SPM).72 The SPM Resolvins, Protectins and Maresins, 
together with AA-produced lipoxins, contribute to the active process of resolution of 
inflammation by inhibiting the influx of neutrophils into the site of inflammation and 
enhancing phagocytosis. Evidence to date is largely derived from rodent studies, with 
confirmation of the role of SPMs in human homeostasis and pathophysiology needed. 
 
Prostaglandins and thromboxanes are produced mainly by the action of COX enzymes on AA 
and EPA. COX-1 is involved in basic physiological functions while COX-2 products are 
mainly produced in response to inflammation and in malignant conditions such as colo-rectal 
cancer.73 COX-2 oxylipin products and COX inhibitors are important modulators of elements 
of the cardiometabolic phenotype, including blood pressure, platelet aggregation and 
atherogenesis.74 In this context, it would be interesting to better understand how the 
differences between nonsteroidal anti-inflammatory drugs (including aspirin), n-3 PUFA, and 
n-6 PUFA on prostaglandin metabolism may relate to their different effects on ASCVD risk 
(e.g. some adverse effects of selective COX-2 inhibitors vs. aspirin).75  
 
Lipoxygenases (encoded by ALOX5, ALOX5AP, ALOX12 and ALOX15) modulate the 
production of the pro-inflammatory LTs and the anti-inflammatory SPMs.76 In obese patients 
with T2DM, increased ALOX5, ALOX12 and ALOX15 expression in adipose tissue has been 
reported compared to obese-nondiabetic patients.77 The ALOX5 enzymatic pathway is 
activated in cardiovascular diseases and suggests an important role of LTs in atherosclerosis 
and in its ischemic complications such as MI and stroke.78 CYP1-4 families produce 
epoxyeicosatrienoic acid (EET) and hydroxyeicosatetraenoic (HETE) from AA, EPA and 
DHA, with EETs being further catalyzed to their respective regioisomers (DiHETE) through 
epoxide hydrolase (sEH). Pre-clinical and clinical studies show the potential role of these 
metabolites as vasodilators and subsequent regulators of blood pressure, with some 
preliminary evidence of their anti-arrhythmic and cardio-protective functions.79   
 
Relationship of desaturase activity to cardiometabolic health 
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The relevance of endogenous formation of more unsaturated FAs from dietary precursor FAs 
(LA and ALA) for cardiometabolic diseases has been investigated across different prospective 
cohorts. Because direct measurement of liver desaturase activity is not possible most reports 
have relied on estimates of activities based on product-to-precursor ratios of FAs measured in 
blood fractions. Several studies observed that a higher estimated delta-6 activity (ratio of 
GLA/LA) is related to an increased T2DM risk, while the contrary was the case for estimated 
delta-5 activity (AA/DGLA).37,58,80 A similar, although less clear picture emerges for 
ASCVD, where a pooled analysis of 30 cohort studies revealed inverse associations for both 
LA and AA. However, studies on ASCVD considering intermediate n-6 PUFA or specific FA 
ratios to reflect their bioconversion are scarce. DGLA was related to higher CHD risk,81 but 
less convincing stroke risk in the ARIC study,82 but GLA and/or DGLA were not clearly 
associated with ASCVD risk in other studies.83-85 Still, these studies suggest overall that 
higher delta-6 activity but lower delta-5 activity, which would both lead to the accumulation 
of intermediate FAs (GLA and DGLA) increase cardiometabolic risk, not a higher 
accumulation of AA.  
 
Genetic determinants of PUFA metabolism 
Genetic factors have been clearly linked to the fatty acid composition of biosamples, 
specifically blood fractions. Variations in FADS1 and FADS2, the genes encoding the delta-5-
and delta-6-desaturases, have been related to PUFA blood levels by candidate gene 
approaches.86 Furthermore, GWAS have identified this region to have the strongest genetic 
link to PUFA blood levels. For example, variant alleles at single nucleotide polymorphisms 
(SNPs) in the FADS1-2-3 gene cluster were associated with higher levels of ALA and lower 
levels of EPA and DPA in the CHARGE consortium.87 The strongest associated SNPs 
explained ~4%, 2% and 9% of the variance of ALA, EPA and DPA, respectively. Similarly, 
variants in the FADS1-2-3 gene cluster were strongly associated with n-6 PUFA levels (LA, 
GLA, DGLA, AA) in CHARGE, with the top SNP (rs174547) explaining ~10% variation in 
DGLA and >20% in AA.88 Similarly, GWAS considering FA ratios as estimates of delta-5- or 
delta-6 desaturase have identified the FADS1-2-3 gene cluster as prominent locus.89,90  
 
In addition to their relationship to tissue FA composition, variants in the FADS1-2-3 gene 
cluster are among the strongest genetic variants linked to TG levels 91,92 and are associated 
with other lipids, e.g. cholesterol.92 Furthermore, GWAS support that variants in this gene 
cluster are among the strongest signals related to specific lipids, particularly phospholipids 
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(phosphatidylcholines and phosphatidyletholamines).93,94 Several of these lipids were related 
to risk of diabetes and ASCVD in prospective studies.95,96  
 
Variants in the FADS1-2-3 gene cluster have not been identified to relate to diabetes and 
ASCVD risk on a genome-wide level,97,98 despite their association with multiple other 
cardiometabolic traits, including inflammatory markers,91 and fasting glucose.99 However, 
they have recently been used in Mendelian randomization analyses to support causal roles of 
desaturases, PUFA and specific phospholipids for cardiometabolic diseases.100-102 However, 
investigating genetic variation in the FADS1-2-3 gene cluster to disentangle the potentially 
different role of PUFA is hampered by strong linkage disequilibrium in this region.80 
Common variants in FADS1 are strongly correlated with variants in FADS2 and minor alleles 
of variants in FADS1 are not only related to higher DGLA (substrate of delta-5-desaturase) 
and lower AA concentrations (product), but also higher LA and lower GLA concentrations 
(substrate and product of delta-6-desaturase) in European populations.88 Importantly in this 
context, prospective studies using PUFA biomarkers support that both desaturases have 
opposing associations with cardiometabolic risk and confounding by linkage disequilibrium in 
genetic studies may mask true associations.103  
 
Also noteworthy, genetic variants in the FADS1-2-3 gene cluster show strong variability in 
allele frequency across different populations. For example, the C-allele of FADS1 rs174547, 
related to lower ability to convert plant based PUFA into longer-chain and more unsaturated 
FAs, is largely absent in African, relatively common in European and dominating in 
American populations (Figure 2).104 Similarly, the FADS2 variant rs174570, related to lower 
desaturase activity, is much more frequent in Greenlandic Inuit (allele frequency 99%) than in 
Chinese (34%) or European populations (16%).105 This highlights a potential human 
adaptation to varying dietary PUFA sources. Variants in the FADS1-2-3 gene cluster which 
increase LC-PUFA synthesis from plant-based PUFA might have been of advantage in 
geographic regions with limited access to marine sources for LC-PUFA. The other extreme 
can be found in native Inuit who traditionally consume extremely high levels of LC n-3 PUFA 
from fish and marine mammals and for whom the FADS1-2-3 gene cluster was found to be 
the strongest outlier region based on patterns of allele frequency differentiation compared to 
other populations.105 There is little evidence that the FADS1-2-3 gene cluster relates to 
systems and biologic processes related to food preferences, e.g. fish consumption.106 
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Genetic variations in ALOX, COX and CYP-450 genes affect oxylipin production.79,107 ALOX 
genotype was associated with cardiometabolic phenotypes in a number of experimental 
models and human investigations. In ALOX5 KO mice, a reduction in LTB4 and reverse 
cholesterol transport suggests a new mechanism through which lipoxygenase pathway likely 
influences atherogenesis.108 Large-scale GWAS reported associations between ALOX5 SNPs 
and HDL-cholesterol levels in humans.92,108 Variation in the tandem repeats of the ALOX5 
promoter and in ALOX5 activating protein (ALOXAP) was associated with incident MI in 
cohort studies.109,110 However, ALOX genotypes were not significantly associated with T2DM 
or coronary artery disease in recent GWAS.71,111 
 
Consequences of altered desaturase and lipoxygenase activity  
The strong association of variants in the FADS1-2-3 gene cluster with tissue PUFA 
concentrations suggests that response to dietary PUFA intake in terms of blood PUFA 
composition is modified by genetic architecture related to the activity of desaturases. 
However, this question has been investigated in few studies to date (Table 2).112-118 
Unfortunately, most studies were cross-sectional in nature or have investigated intake of LC 
n-3 PUFA intake,112,114,116,118 which are, however, not the substrate of desaturases. Only two 
trials investigated supplementation with plant-derived PUFA. Gillingham et al. investigated 
the effect of a ALA-rich flaxseed oil intervention in comparison to a Western diet and an oleic 
acid rich diet. Minor allele carriers of 4 different variants in the FADS1-2-3 gene cluster had 
substantially lower increase in EPA plasma concentrations after the ALA intervention 
compared to wild-type: EPA levels in individuals homozygote for the major FADS1 rs174561 
allele were 2·2% (ALA intervention) versus 0·6% (Western diet) and 0·7% (oleic acid diet) 
after the intervention, but 0·9% versus 0·3 and 0·4% in individuals being homozygote for the 
minor allele (P for interaction <0·001).115 In the FADSDIET trial, AA levels in plasma 
phospholipids decreased in participants with the rare CC genotype of FADS1 rs174550 in 
response to a LA-rich sunflower oil, while AA levels remained unchanged in individuals with 
the TT genotype.117 These findings are supported by animal studies. Knockout of FADS2 in 
mice fed a LA-rich diet is related to lower availability of AA 119 and incorporation of AA into 
phospholipids.120 Similarly, knockout of FADS2 depletes EPA and DHA in mice fed an ALA-
rich diet.121 FADS2 variants alter FADS2 gene expression and tissue AA concentration in 
pigs.122 Similarly, FADS1 knockdown results in reorganization of both n-6 and n-3 PUFA 
levels and their associated proinflammatory and proresolving lipid mediators.123  
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Similar to modifying effects on blood PUFA levels, modification of effects of dietary PUFA 
on blood lipid levels by variants in the FADS1-2-3 gene cluster can be hypothesized. Studies 
addressing this question have found mixed results, but are mostly observational and cross-
sectional in nature (Table 2).113,124,125 Only one trial, involving 208 participants, has 
specifically focused on the triglyceride response to dietary LC n-3 PUFA intervention, but did 
not observe an effect modification.126 However, as mentioned above, LC n-3 PUFA are not 
the main substrate of desaturases. Given the current lack of interventional studies which 
directly tested response to the intake of plant derived LA and ALA rather than LC n-3 PUFA, 
this hypothesis remains unconfirmed so far. Still, modifying effects of the FADS1-2-3 gene 
cluster have been described for other cardiometabolic risk factors. For example, the 
FADSDIET trial observed modification of a LA-rich diet response by FADS1 rs174550 in 
terms of inflammation (hsCRP).118 Influences of inhibited delta-5- and delta-6-desaturase 
activities on glycaemic traits and atherosclerosis have been described from knock-out animal 
studies.127 
 
Whether variants in the FADS1-2-3 gene cluster modify cardiometabolic effects of dietary 
PUFA in terms of risk for clinical endpoints has been investigated in two case control and 
several cohort studies (Table 2).49,58,128-130 In a Swedish cohort study, higher ALA intake 
appeared to be more beneficial with regard to ASCVD risk among carriers of FADS1 
rs174546 genotype related to lower desaturase activities.129 While FORCE, a consortium of 
several prospective cohort studies, did not find that the FADS1 rs174547 variant modulated 
the relationship between LA and AA biomarkers and T2DM risk,58 but effect modification 
was observed for ASCVD endpoints, specifically stroke.49 The latter finding implies that a 
protective effect of higher LA is restricted to individuals homozygous for the common 
rs174547 allele, thus a higher genetically determined ability to convert LA to AA and 
subsequent products. Still, the FADS1 variant considered has already strong influence on LA 
tissue concentrations and interpretation of this PUFA biomarker as a proxy of dietary intake is 
problematic. Clearly, prospective studies investigating associations between intake of plant-
derived LA and ALA and subsequent risk of diabetes and ASCVD and its modification by 
variants in the FADS1-2-3 gene cluster would be informative to substantiate the findings of 
FORCE.  
 
With regard to potential modification of dietary PUFA effects by ALOX5, evidence from 
studies is more limited. AA intake was related to enhanced influence of the variant 
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rs59439148, related to the number of tandem repeats of the Sp1 binding site in the ALOX5 
promoter (the rare allele having 1-2 fewer tandem repeats), on arterial thickness in a cross-
sectional study 131 and with the incidence of MI in a cohort study.109 However, in the Danish 
Diet, Cancer and Health study, the same tandem repeat variant in ALOX5 did not interact with 
adipose tissue AA and EPA in relation to risk of MI.132 In an intervention, individuals 
homozygote for the rare variant (deletion of tandem repeats) showed less increase in 
erythrocyte EPA and DHA levels in response to a fish oil supplementation compared to 
subjects with the common allele.133 Similarly, concentrations of EPA derived metabolites 
showed a more marked increase after the fish oil supplementation in individuals homozygote 
for the common allele compared to carriers of the rare allele.134 Still, results of this small-
scale trial have not been replicated so far.  
 
Implications 
Intake of n-6 PUFA varies largely across different global regions, ranging from 2·5% to 8·5% 
of daily energy according to the Global Burden of Disease Study (GBDS).10 In Western 
Europe and the USA, mean intake is estimated to be 5·2 and 6·7% of daily energy. Even more 
pronounced differences in intake levels of n-3 PUFA are evident, where, for example, with 
LC n-3 PUFA from seafood ranging within Western Europe between ~100 mg/d (Ireland) to 
~1200 mg (Denmark and Iceland), with a mean USA consumption of ~140mg/d. The intake 
of plant n-3 PUFA (ALA) ranges 10-fold across global regions from ~300-3200 mg/day, 
which standardized to a 2000 kcal per day represents <1 to 14% of daily energy intake.   
 
Reference values for adults according to EFSA are 4% of energy from LA and 0·5% from 
ALA.135 These values are based on the lowest estimated mean intakes of various populations 
across Europe, where overt deficiency symptoms are not present – they do not reflect optimal 
intake levels for the prevention of cardiometabolic diseases. Interestingly, reference values for 
n-3 and n-6 PUFA vary between EFSA and several European countries.2 Ranges of intake for 
LA as an energy source that is associated with reduced risk of chronic disease while providing 
intakes of essential nutrients, has been specified by the US Institute of Medicine (5-10%) 136 
and the FAO/WHO (2·5–9·0%).137 This implies that LA intakes exceeding these ranges are 
considered sub-optimal and potentially harmful, which is in contrast to EFSA 
recommendations where no upper limit for n-6 PUFA was set.135 With regard to 
recommendations for LC n-3 PUFA intake, adequate intake levels have been more 
comparably set at 250-500mg/d EPA+DHA by most organizations.135-138 
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Guidelines and position statements of the American Heart Association 17 and the European 
Society of Cardiology 139 regarding the role of PUFA in the prevention of ASCVD highlight 
the importance of substituting energy from SFA by PUFA, but are less optimistic for LC n-3 
PUFA. Specifically, the intake of fish oil supplements with dosages of EPA and DHA 
substantially higher than the adequate intake level is not routinely recommended at a 
population level. The American Heart Association, however, evaluates fish oil 
supplementation to be a reasonable (but not recommended) treatment for secondary 
prevention among patients with pre-existing CHD.17 Beneficial effects of fish oils observed in 
subgroups of low-fish consumers in some trials 7 also indicates cardio-protection in those with 
low EPA+DHA status, an area which needs closer attention in further research. Both societies 
recommend a usual intake of 1-2 portions of fish per week, mainly based on their role as 
dietary sources of LC n-3 PUFA.139,140 The inconsistent literature on fish intake (beneficial, 
but largely based on observational studies) and individual fish oil supplementation trials 
demonstrates the complexity of comparing food bioactives in isolation to their complex food 
sources. Still, given the observed ASCVD risk reduction when evidence from recent trials is 
included in meta-analysis 22 implies that the more conservative recommendations regarding 
EPA and DHA supplementation may need to be revised. 
 
The strong role of PUFA metabolism, specifically of desaturases, highlights that fatty acid 
intakes and availability along with genetic variants which influence PUFA metabolism, might 
be considered in the future when setting ALA, EPA and DHA recommendations (Figure 3). 
In regions with limited access to seafood, intake of the plant-derived ALA might need to be 
considerably higher, specifically if genetic variants in the FADS1-2-3 gene cluster are present 
which limit bioconversion of ALA to LC n-3 PUFA. Alternatively, supplementation with 
fish-oil would be an option in such a setting. Similarly, if plenty of plant oils rich in LA and 
ALA are consumed and the genetic make-up supports bioconversion to longer-chain, more 
unsaturated PUFA, there could be a lower need for intake of LC n-3 PUFA from seafood or 
supplements.  
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Search strategy and selection criteria 
PubMed database was searched for systematic review articles written in English from January 
1990 up to August 2019, to identify reports about associations of PUFA intake and 
cardiometabolic outcomes. The search terms used were “PUFA”, “Polyunsaturated fatty 
acids”, “linoleic acid”, alpha-linolenic acid”, “eicosapentaenoic acid”, “docosahexaenoic 
acids”, “n-3 fatty acids”, “n-6 fatty acids” together with terms for cardiovascular outcomes 
and T2DM. The reference lists of the identified papers were used to identify individual papers 
of interest. Furthermore, we search PubMed database for studies on interaction of FADS gene 
variants and PUFA intake using search terms “FADS1”, “FADS2”, “fatty acid desaturase”, 
“D5D”, “Delta-5-Desaturase”, “D6D”, “Delta-6-Desaturase”, “FADS polymorphisms”, 
“FADS gene variants” in combination with “PUFA”, “Polyunsaturated fatty acids”, “linoleic 
acid”, alpha-linolenic acid”, “eicosapentaenoic acid”, “docosahexaenoic acids”, “n-3 fatty 
acids”, “n-6 fatty acids”. The final reference list was selected on the basis of relevance to the 
subject of this review. 
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Figure 1 Key enzymes involved in the metabolism of PUFA 
Conversion of linoleic acid and α-linolenic acid to longer-chain n-6 and n-3 polyunsaturated 
fatty acids is catalized by the action of delta-6 desaturase, delta-5 desaturase, and elongases. 
Arachidonic acid (AA), eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) often 
exert their physiological effects through ‘oxylipins’ produced by the action of cycloxygenases 
(COXs), lipoxygenases (ALOXs), and some members of CYP450 superfamily. 
2-PGs: 2 series prostaglandins, 3-PGs: 3 series prostaglandins 4-LTs: 4 series leukotrienes, 5-
LTs: 5 series leukotrienes, ALOXs: Arachidonate Lipoxygenases, ALOX5AP: 5-
Lipoxygenase Activating Protein, COX-2: cylcloxygenase-2, CYP-450: cytochrome-P450,  
DHEQs: dihydroxyeicosatetraenoic acids, DHET: dihydroxyeicosatrienoic acid, DiHDPA: 
dihydroxydocosapentaenoic acid, EDP: epoxydocosapentaenoic acid, EEQ: 
epoxyeicosatetraenoic acid, EETs: epoxyeicosatrienoic acid, HDHA: 
hydroxydocosahexaenoic acid, HEPE: hydroxyeicosapentaenoic acid, HETE: hydroxy-
eicosatetraenoic acid, HpDHA: hydroperoxide intermediate of DHA, sEH: serum epoxide 
hydrolase enzyme, TX: thromboxanes 
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Figure 2. Allele frequencies (percent) for FADS1 rs174547 across populations 
Genetic variation in FADS1 is in strong linkeage disequilibrium with variation in FADS2. 
FADS1 rs174547, one of the lead SNPs related to circulating PUFA levels identified in large-
scale GWAS,88 shows strong differences across different populations worldwide. Data from 
1000 Genomes Project Phase 3.104   
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Figure 3. Conceptual framework for hypothesized cardiometabolic benefits of n-6 and n-
3 PUFA intake depending on genetic variation in PUFA metabolism 
Genetic variation in the FADS1-2-3 gene cluster relates to the activity of d-5 and d-6-
desaturases, key enzymes in the formation of longer-chain FA from precursor n-3 α-linolenic 
acid (ALA) and n-6 linoleic acid (LA). Mutations related to lower desaturase activity are 
frequent in Native Inuit (e.g. rs174570: 99% 105), relatively common in European populations 
(16%) and largely absent in African populations (1%).104 Higher d5-desaturase activity and 
thus higher ability to metabolize LA and intermediate n-6 PUFA (GLA and DGLA) to AA is 
related to lower cardiometabolic risk.49 In the presence of high intake of LC n-3 PUFA from 
fish and seafood, a lower genetically determined desaturase activity may compensate for a 
decreased intake of plant-based PUFAs. However, there is uncertainty whether higher ALA 
intake is more beneficial in the context of higher ability to convert ALA to LC n-3 PUFA.128 
 
 
Table 1: Key RCTs examining the impact of PUFA supplementation on incident cardiovascular disease   
 
Study/ 
Publication 
year 
Population Intervention Durat
ion 
Outcome Effect size  
HR or RR (95% 
CI) 
Comment 
GISSI 12 Post-MI < 3m 850-882 
mg/d 
EPA+DHA 
3·5y P: Death, MI stroke 
S: ASCVD death  
0·85 (0·74-0·9) 
0·70 (0·56-0·87) 
4 medications prescribed, statins use 
5% 
JELIS 14 Hypercholesterole
mic men (40-75y) 
and ostmenopausal 
women 
1800mg 
EPA 
(ethyl 
esters) 
 
4·6y P: sudden cardiac death, 
fatal and non-fatal MI, 
unstable angina, 
angioplasty, stenting, 
CABG  
0·81 (0·69-0·95) All on statins, 64% on 
antihypertensive medication, 14% 
on antiplatelets, 12% on 
hypoglycemic agents 
Alpha 
Omega 13 
Post-MI 1: 400 mg/d 
EPA+DHA 
(trigylceride
s)   
2: 2 g/d 
ALA 
3·7y P: fatal and nonfatal 
ASCVD, PCI+CABG 
EPA+DHA vs. 
ALA/placebo: 
1·01 (0·87-1·17) 
 
ALA vs. 
EPA+DHA/place
bo: 
0·91 (0·78-1·05) 
Median EPA+DHA intake at 
baseline: 120-130 mg/d, no 
subgroup difference by baseline 
intake; 
Suggestive effect of ALA in women 
(HR: 0·73 (0·51–1·03)) 
ORIGIN 19 High ASCVD risk 
and 
prediabetes/diabete
s 
900 mg/d 
EPA+DHA 
(ethyl 
esters) 
6·2 y P: ASCVD death 
S: nonfatal MI, stroke 
or ASCVD death 
0·98 (0·87-1·10) 
1·01 (0·93-1·10 
High prevalence of cardiovascular 
medication, statin use ~54%; 
Median EPA+DHA intake at 
baseline: 210 mg/d 
Risk and 
Prevention 
Study 16 
ASCVD risk 
factors ≥4 or 
vascular disease, 
previous MI 
precluded 
850 mg/d 
EPA+DHA 
(ethyl 
esters) 
5·0y P: Time to death from 
ASCVD or hospital 
admission for ASCVD 
S: ASCVD death 
0·98 (0·88-1·08) 
 
1·03 (0·82-1·30) 
9 medications prescribed, statin use 
41% 
At 1y, event rate lower than 
anticipated, 
the primary end point was revised 
 
Tables
ASCEND 6 Type 2 diabetes, no 
evidence of 
ASCVD 
840 mg/d 
EPA+DHA 
(ethyl 
esters) 
7·4y P: ASCVD death, MI, 
stroke, transient 
ischemic attack 
S: nonfatal MI 
S: nonfatal ischemic 
stroke 
S: vascular death 
1·00 (0·91-1·09) 
 
0·93 (0·76-1·14) 
1·01 (0·84-1·22) 
0·81 (0·67-0·99) 
High prevalence of cardiovascular 
medication, statin use ~75% 
VITAL 7 Healthy, men 
(≥50y), women 
(≥55y) 
840 mg/d 
EPA+DHA 
(ethyl 
esters) 
5·3y P: ASCVD death, MI 
and stroke 
S: ASCVD death 
S: Total MI 
0·92 (0·80-1·06) 
0·96 (0·76-1·21) 
0·72 (0·59-0·90) 
 
HR of ASCVD death, MI and stroke 
of 0·81 (0·67-0·98) and total MI of 
0·60 (0·45-0·81) with fish intake of 
<1·5 servings per week. No effect in 
those with higher fish intakes of 
≥1·5 servings per week (HR 1·08 
and 0·94) 
REDUCE-IT 
15 
ASCVD or T2DM 
≥ 1 ASCVD risk 
factor, high TG  
4 g/d Ethyl-
EPA 
(icosapent 
ethyl) 
4·9y P: ASCVD death, MI, 
stroke,  
coronary 
revascularization or 
unstable angina 
0·75 (0·68-0·83) HR of 0·74 (0·65–0·83) in 
composite ASCVD death, MI and 
stroke secondary end point 
 
STRENGTH 
28,29 
high ASCVD risk 
or previous 
ASCVD or DM, 
high TG and low 
HDL-c 
4g oil 
providing 
2·2 EPA + 
0·8g DHA 
(carboxylic 
acids) 
- P: cardiovascular death, 
nonfatal MI, nonfatal 
stroke, 
emergent/elective 
coronary 
revascularization, or 
hospitalization for 
unstable angina 
stopped Intervention judged unlikely to 
demonstrate a benefit by the 
independent data monitoring 
committee  
       
LA veterans 
38 
Men with or 
without CHD  
Corn and 
soybean oil 
≤8y MI, sudden death + 
cerebral infarction 
0·74 (0·53-1·03) 
 
Confirmation of compliance by 
adipose tissue fatty acid analyses. 
Secondary outcome for total 
ASCVD showed ~ 30% reduced 
risk, RR of 0.68 (0.52–0.91). 
MRC Soy 39  Post MI, men Soybean oil 
~80g  
5y MI, sudden death and 
all-cause mortality 
0·86 (0·61-1·22) Confirmation of compliance by 
weighted food-records and adipose 
tissue fatty acid analyses. ≥43 g 
soybean oil unheated (often drunk 
with fruit juice)  
Oslo diet-
heart study 40 
Post MI, men Soybean oil, 
Cod liver oil 
5y MI + Sudden cardiac 
death 
0·75 (0·57-0·99) Multifactorial intervention with 
modification of dietary composition 
other than fat 
Finnish 
mental 
hospital 
study 41 
 
Men with MI Soybean oil 6y MI (ECG change) + 
CHD mortality  
0·55 (0·34-0·88) Institutionalized population; 
assignment by hospital, not 
individually randomized; 
confirmation of compliance with a 
large increase of LA in adipose 
tissue.  
Finnish 
mental 
hospital 
study 42 
Women with MI Soybean oil 6y MI (ECG change) + 
CHD mortality 
0·64 (0·41-1·00) Institutionalized population; 
assignment by hospital, not 
individually randomized 
Minnesota 
Coronary 
Survey  
43 
Men and women Corn oil ≤4·5y ASCVD events, 
ASCVD and total 
mortality 
1·08 (0·84-1·37) Institutionalized population; mean 
follow-up only 1 year; drop-out rate 
~75%; very high dose of corn oil (13 
vs 3 energy % from LA) 
Sydney Diet 
Heart Study 
44 
Post MI or with 
CHD, men  
Safflower 
oil 
2-7y MI + cardiac death 1·86 (0·63-5·44) Relatively short study duration 
(median follow-up 39 months),  with 
potential confounding by trans-fatty 
acids; very high dose of n-6 PUFA, 
without any increase of n-3 
The table does not provide an exhaustive description of all PUFA interventions conducted to date, but rather gives illustrative examples of earlier and more recent trials, and those 
which are discussed in the text  
ASCVD- atherosclerotic cardiovascular disease, CABG- coronary artery bypass graft, CHD- coronary heart disease, CI- confidence interval, DHA- docosahexanoic acid, EPA- 
eicosapentanoic acid, HR- hazard ratio, MI- myocardial infarction, P-primary end-point, PCI- percutaneous coronary intervention, S- secondary end-point, TG- triglycerides 
Table 2. Studies investigating interactions between PUFA intake or status and variants in the FADS1-2-3 gene cluster and FA levels or 
cardiometabolic outcomes 
       
Author/ 
Publication year 
Design, 
Population 
Intervention/Exposure Genetic 
variants 
Outcome Interaction 
 
Fatty acid composition of blood fractions or breast milk 
Molto´-
Puigmartı´ et al. 
2010 112 
Cross-sectional Fatty fish intake rs174575 Plasma and milk 
FA 
Higher EPA or DHA content in human 
milk with higher fatty fish intake only in 
major allele carriers; 
No difference in plasma phospholipid EPA 
or DHA by genotype 
Dumont et al. 
2011 113 
Cross-sectional Dietary LA and ALA rs174546 Serum 
phospholipid FAs 
No interaction  
 
Al-Hilal et al. 
2013 114 
RCT, 
healthy subjects  
EPA+DHA (0·45, 0·9, 
and 1·8 g/day), 
rs174537, 
rs174561, 
rs3834458 
Plasma and RBC 
FA 
Increase in D5D activity (AA:DGLA) 
among T-allele carries of rs174537 with 
higher supplementation 
Gillingham et 
al. 2013 115 
RCT, 
hyperlipidemic 
subjects  
ALA rich diet (20·6 g 
ALA/d) 
rs174545, 
rs174583, 
rs174561, 
rs174537 
Plasma FA Substantially smaller absolute EPA in 
minor allele carriers after ALA 
intervention 
Smith et al. 
2015 118 
Cross-sectional 
(consortium) 
Dietary LA and ALA rs174538, 
rs174548 
Plasma or RBC LC 
n-3 PUFA 
Interaction between ALA intake and 
FADS1 variants on DPA and DHA 
Takkunen e al. 
2016 116 
Cross-sectional LC n-3 PUFA from fish  Plasma and RBC 
FA 
Stronger association between LC n-3 
PUFA intake and EPA in minor allele 
carriers  
Juan et al. 2018 
141 
Cross-sectional Dietary LA, ALA, 
EPA, DHA 
rs174546 Plasma FA Stronger positive associations between 
EPA and DHA intake and EPA 
concentrations with intake with minor T 
allele; no interactions for other dietary 
PUFA 
Lankinen et al. 
2019 117 
Single group 
trial 
LA rich sunflower oil 
(17-28 g LA/d) 
rs174550 Plasma 
phospholipid and 
cholesterol ester 
FA 
Decrease in AA in homozygote for minor 
allele, no effect in homozygote for major 
allele 
 
Blood lipids 
Lu et al. 2010 
124 
Cross-sectional Dietary n-6 and n-3 
PUFA 
rs174546, 
rs482548,  
rs174570 
Total, HDL-, and 
non- 
HDL-cholesterol 
No interactions for total dietary n-3 intake 
and all outcomes; 
No interactions for dietary n-6 and most 
outcomes (only significant interaction for 
HDL-cholesterol and rs174546) 
Dumont et al. 
2011 113 
Cross-sectional Dietary LA and ALA rs174546 Serum TG, 
cholesterol, and 
lipoproteins 
Lower total and non-HDL cholesterol in 
minor allele carriers with high ALA intake 
only 
Cormier et al. 
2012 126 
Single group 
trial 
1·9 g EPA and 1·1 g 
DHA per day 
Selected SNPs 
of the FADS1-
2-3 gene 
cluster 
Plasma TG No interaction observed 
Standl et al. 
2012 125 
Cross-sectional Dietary n-3 PUFA FADS1-2-3 
gene cluster 
Total cholesterol, 
HDL-cholesterol, 
LDL-cholesterol, 
TG 
No interaction observed 
Dumont et al. 
2018 142 
Cross-sectional Dietary LA and ALA rs174547 HDL-cholesterol Lower HDL-cholesterol with minor allele 
only with high LA intake; no interaction 
with ALA 
 
ASCVD or T2DM risk 
Baylin et al. 
2007 128 
Case-control Adipose tissue ALA common 
FADS1 
deletion [T/-] 
Non-fatal MI 
 
No interaction observed 
Hellstrand et al. 
2014 129 
Cohort Dietary LA and ALA rs174546 ASCVD Inverse association of ALA:LA ratio or 
ALA with ASCVD/stroke only in minor 
allele carriers 
Liu et al. 2015 
143 
Case-control Dietary EPA and DHA rs174547 Coronary artery 
disease 
Common T-allele associated with higher 
risk only among individuals with lower 
dietary EPA/DHA intake  
Wu et al. 2017 
58 
12 Cohorts LA and AA biomarker rs174547 Type 2 diabetes No interaction 
Marklund et al. 
2019 49 
13 Cohorts LA and AA biomarker rs174547 ASCVD Inverse association of LA with total 
ASCVD and stroke in homozygote 
common allele carriers, not in minor allele 
carriers; no interactions for ASCVD 
mortality or total CHD or for AA 
ALA- alpha-linolenic acid, ASCVD- atherosclerotic cardiovascular disease, CHD- coronary heart disease, CI- confidence interval, DGLA- dihomo-gamma linolenic acid, DHA- 
docosahexanoic acid, EPA- eicosapentanoic acid, HR- hazard ratio, LA- linoleic acid, MI- myocardial infarction, P-primary end-point, s-secondary end-point, TG- triglycerides 
 
 
AA
COX-2
ALOXs
CYP-450
- 2-PGs (PGE2,PGD2, PGF2α)
- PGI2
- TXA2->TXB2
ALOX
12/15
ALOX5
4-LTs: LTA4->LTC4 ->LTD4 ->LTE4
LTB4
5-HETE
ALOX5AP
+
12/15-HETE
Lipoxins
(LXA4&LXB4)
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